Your session is about to expire
← Back to Search
Unknown
Intervention 1 for Epilepsy
Phase 1
Waitlist Available
Research Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 days
Awards & highlights
Summary
This trial is testing a new drug called OPC-214870 to help people with epilepsy who do not get better with current medications. The drug works by affecting certain brain pathways to reduce seizures.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 3 days
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 days
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Standardized Photosensitivity Range (SPR)
Secondary study objectives
Onset and duration of SPR
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Intervention 1Experimental Treatment2 Interventions
Single dose; up to 400 mg capsule; adaptive dosage determined by initial dosing from cohort 1.Potential for a matching placebo dose to be administered.
Group II: PlaceboPlacebo Group2 Interventions
Single dose; potential for a matching OPC-214870 dose to be administered.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
OPC-214870
2020
Completed Phase 1
~20
Find a Location
Who is running the clinical trial?
Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
264 Previous Clinical Trials
170,064 Total Patients Enrolled
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger